Publication | Closed Access

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

InflammationRheumatologyAutoimmune DiseaseModerate-to-severe Ulcerative ColitisImmunologyGastroenterologyPathologyMaintains Clinical RemissionAdalimumab InducesAutoimmunityInflammatory Rheumatic DiseaseUlcerative ColitisMedicineInflammatory Disease